c-met mRNA在乳腺癌術后腋窩引流液中表達的意義_《中國普外基礎與臨床雜志》

作者：

楊衛軍 ¹ , 黃志剛 ¹ , 李春來 ¹ , 吳正陽 ¹ , 尹家俊 ²

1.貴陽市第一人民醫院普外科(貴陽550002);;
2.大連大學附屬中山醫院普外科(大連116001);

關鍵詞：

乳腺癌微轉移逆轉錄-聚合酶鏈反應 c-met mRNA

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討c-met mRNA在乳腺癌患者術后腋窩引流液中表達的意義。
方法　用RT-PCR法檢測乳腺癌患者術后腋窩引流液中c-met mRNA的表達，分析其表達與腫瘤大小、腋窩淋巴結轉移、雌激素受體（estrogen receptor,ER）、孕激素受體（progesterone receptor,PR）及生長因子受體2（c-erbB-2）的關系，以及5-FU加蒸餾水沖洗手術野對c-met mRNA表達的影響。
結果　①c-met mRNA能在乳腺癌術后腋窩引流液中表達，其陽性率高于病理檢查腋窩淋巴結轉移的陽性率(P＜0.05)。②腋窩淋巴結轉移、腫瘤大小與c-met mRNA的表達有關。③腫瘤ER、PR 及c-erbB-2的表達與c-met mRNA的表達無關。④5-FU加蒸餾水沖洗手術創面能明顯降低c-met mRNA的表達。
結論　c-met mRNA是乳腺癌微轉移研究的理想特異性標志物，與常規病理檢查腋窩淋巴結相比，RT-PCR檢測腋窩引流液中c-met mRNA的表達能更早檢測出腫瘤細胞在胸壁淋巴管中的轉移，并具有更高的準確性。

引用本文： 楊衛軍,黃志剛,李春來,吳正陽,尹家俊. c-met mRNA在乳腺癌術后腋窩引流液中表達的意義. 中國普外基礎與臨床雜志, 2007, 14(3): 259-262. doi: 復制

1.	傅西林，張立華，張國珩. 常規檢查淋巴結轉移陰性之乳腺癌腋窩組織再連續切片檢查的研究 [J]. 中國腫瘤臨床， 1985； 12（1）∶20.
2.	陳朝倫，盧曉梅，黃絨，等. Ⅰ期癌癥患者切除淋巴結內隱匿性微小轉移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志， 1997； 19(1)∶69.
3.	Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg， 1993; 218(3)∶270.
4.	Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg， 2002; 89(1)∶21.
5.	張維銘. 現代分子生物學實驗手冊 [M]. 北京：科學出版社， 2003∶103~106.
6.	Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res， 2001; 61(20)∶7518.
7.	Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis， 2001; 22(7)∶1035.
8.	Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol， 1994; 144(4)∶675.
9.	Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res， 1994; 54(7)∶1630.
10.	Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene， 1991; 6(11)∶1997.
11.	Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun， 1992; 189(1)∶227.
12.	Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene， 1992; 7(12)∶2549.
13.	Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene， 1992; 7(1)∶181.
14.	陳顯玉，喻梅英，楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉化生長因子α的表達及意義 [J]. 中國普外基礎與臨床雜志, 1999; 6(2)∶81.
15.	尹家俊，宋燕. 肝細胞生長因子及受體c-met在乳腺癌中的研究進展 [J]. 中國普外基礎與臨床雜志, 2000; 7(5)∶347.
16.	Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer， 2003; 97(8)∶1841.
17.	Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol， 1999; 21(5)∶397.
18.	Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer， 1998; 82(8)∶1513.
19.	徐叔云主編. 中華臨床藥物學 [M]. 北京：人民衛生出版社， 2003∶1429.
20.	Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res， 1995; 15(4)∶1543.

1. 傅西林，張立華，張國珩. 常規檢查淋巴結轉移陰性之乳腺癌腋窩組織再連續切片檢查的研究 [J]. 中國腫瘤臨床， 1985； 12（1）∶20.
2. 陳朝倫，盧曉梅，黃絨，等. Ⅰ期癌癥患者切除淋巴結內隱匿性微小轉移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志， 1997； 19(1)∶69.
3. Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg， 1993; 218(3)∶270.
4. Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg， 2002; 89(1)∶21.
5. 張維銘. 現代分子生物學實驗手冊 [M]. 北京：科學出版社， 2003∶103~106.
6. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res， 2001; 61(20)∶7518.
7. Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis， 2001; 22(7)∶1035.
8. Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol， 1994; 144(4)∶675.
9. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res， 1994; 54(7)∶1630.
10. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene， 1991; 6(11)∶1997.
11. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun， 1992; 189(1)∶227.
12. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene， 1992; 7(12)∶2549.
13. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene， 1992; 7(1)∶181.
14. 陳顯玉，喻梅英，楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉化生長因子α的表達及意義 [J]. 中國普外基礎與臨床雜志, 1999; 6(2)∶81.
15. 尹家俊，宋燕. 肝細胞生長因子及受體c-met在乳腺癌中的研究進展 [J]. 中國普外基礎與臨床雜志, 2000; 7(5)∶347.
16. Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer， 2003; 97(8)∶1841.
17. Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol， 1999; 21(5)∶397.
18. Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer， 1998; 82(8)∶1513.
19. 徐叔云主編. 中華臨床藥物學 [M]. 北京：人民衛生出版社， 2003∶1429.
20. Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res， 1995; 15(4)∶1543.

《中國普外基礎與臨床雜志》

c-met mRNA在乳腺癌術后腋窩引流液中表達的意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

c-met mRNA在乳腺癌術后腋窩引流液中表達的意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料